Kirkland at ARDD2026: Small coordinated trials for gerotherapeutics
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedIn the supplied description, James Kirkland's ARDD2026 talk is summarized as saying small, coordinated trials are showing safety and early efficacy of targeting fundamental aging processes while responsive biomarker sets are built. [1]
The description summarizes Kirkland's key takeaway as small, coordinated trials showing safety and early efficacy of targeting fundamental aging processes while building responsive biomarker sets. [1]
According to the description, ARDD made its North American debut in Boston at Harvard University on October 1-3, 2026. [1]
Kirkland talk on gerotherapeutic trial strategies
The description says James Kirkland of Cedars-Sinai Medical Center presents at the 13th Aging Research and Drug Discovery Meeting on new clinical trial strategies for gerotherapeutics, under the Translational Geroscience Network. The stated key takeaway is that small, coordinated trials are showing safety and early efficacy of targeting fundamental aging processes while building responsive biomarker sets. These are the description's characterizations of the talk, not results of a study reported in detail. [1]
ARDD2026 as described: Boston meeting context
The description presents ARDD as a conference dedicated to longevity biotechnology that brings together researchers, pharmaceutical executives, regulators, entrepreneurs and investors. It says ARDD was founded by Alex Zhavoronkov in 2014 and made its North American debut in Boston at Harvard University on October 1-3, 2026, opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health. A long sponsor list is given. None of this is evidence about the trials themselves. [1]
What the description does not establish
The description gives no trial names, participant numbers, comparators, follow-up periods, outcome measures or numerical results, and no specific biomarkers are named. It does not say which aging processes were targeted or in which populations. The safety and early efficacy wording is attributed to the talk as summarized, so it should not be read as confirmed clinical benefit. [1]
Context & limits
Only the video description was supplied; the video and transcript were not reviewed. The description gives no trial names, sample sizes, comparators, follow-up, outcomes or numerical results, and names no specific biomarkers. Safety and early efficacy are the description's summary of the talk, not verified findings.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
Small, coordinated trials are showing safety and
made its North American debut in Boston
About this video
Creator description · original textText language: English
ARDD · 21 min · Source published: 2026-10-20
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.